Acquisition of King Pharmaceuticals, Inc. (Tables)

6 Months Ended

Jul. 03, 2011

Schedule Of Recognized Identifiable Assets Acquired And Liabilities Assumed As Part Of Business Combination [Text Block]

The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date.

(millions of dollars)	Amounts Recognized as of Acquisition Date (Provisional)

Working capital, excluding inventories	$	190
Inventories		338
Property, plant and equipment		413
Identifiable intangible assets, excluding in-process research and development		1,781
In-process research and development		301
Net tax accounts		(373	)
All other long-term assets and liabilities, net		114
Total identifiable net assets		2,764
Goodwill		791
Net assets acquired/total consideration transferred	$	3,555

Schedule Of Business Acquisition Included In Condensed Consolidated Statements Of Income [Text Block]

The following table presents information for King that is included in Pfizer’s condensed consolidated statement of income from the acquisition date, January 31, 2011, through Pfizer’s second-quarter 2011 domestic and international quarter-ends:

(millions of dollars)	King’s Operations Included in Pfizer’s Second-Quarter 2011 Results			King’s Operations Included in Pfizer’s Six-Month 2011 Results

Revenues	$	357		$	581
Loss from continuing operations attributable to Pfizer Inc. common shareholders(a)		(5	)		(74	)

(a)

Includes purchase accounting adjustments related to the fair value adjustments for acquisition-date inventory estimated to have been sold ($61 million pre-tax in the second quarter of 2011 and $119 million pre-tax in the first six months of 2011), amortization of identifiable intangible assets acquired from King ($43 million pre-tax in the second quarter of 2011 and $71 million pre-tax in the first six months of 2011) and restructuring and integration costs ($63 million pre-tax in the second quarter of 2011 and $159 million pre-tax in the first six months of 2011).

Schedule of pro forma information related to the acquisition [Text Block]

The following table presents supplemental pro forma information as if the acquisition of King had occurred on January 1, 2010:

	Pro Forma Consolidated Results
	Three Months Ended		Six Months Ended
(millions of dollars, except per share data)	July 4, 2010		July 3, 2011		July 4, 2010

Revenues	$	17,465	$	33,595	$	34,414
Income from continuing operations attributable to Pfizer Inc. common shareholders		2,408		5,008		4,314
Diluted earnings per share attributable to Pfizer Inc. common shareholders		0.30		0.63		0.53

- Definition

Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.

+ References+ Details